Korean Ministry of Food and Drug Safety (MFDS) approved the Investigational New
Drug Application (IND) for ISU Abxis’s ‘ISU104(Human Monoclonal
Antibody Targeting ErbB3)’ in August, 2017.
is a receptor protein that is overexpressed in various types of human cancers.
It is a protein that plays an important role in tolerance of ‘EGFR’ and ‘HER2’
targeted anti-cancer drugs. Binding with cancer-induced signaling receptor ‘ErbB1’
or ‘ErbB2’, ‘ErbB3’ generates cancer cells to grow.
ISU Abxis plans to initiate a Phase 1 clinical dose finding study in patients
with advanced solid tumors to assess the safety, tolerability and
pharmacokinetics of ‘ISU104’ in the third quarter of 2017.